Strong Leg Muscles Linked to Lower Metabolic Syndrome Risk in Obese Youth: Study

Italy: A small study published in the European Journal of Pediatrics has revealed that children and adolescents with obesity who have stronger leg muscles are at a lower risk of developing metabolic syndrome (MetS). Researchers emphasized the importance of promoting physical activity from an early age to support muscle integrity and long-term metabolic health.

The cross-sectional study, conducted by Alessandro Gatti and colleagues from the Laboratory of Adapted Motor Activity (LAMA) at the University of Pavia, examined the association between physical fitness and metabolic syndrome severity in children with obesity. Metabolic syndrome, characterized by a cluster of cardiometabolic risk factors including high blood pressure, abnormal lipid levels, and increased waist circumference, is increasingly observed in the pediatric population, particularly in those with obesity.

The researchers assessed 62 children and adolescents aged 7–17 years with a BMI z-score greater than two standard deviations. Physical fitness was evaluated across three domains: cardiorespiratory fitness, muscular strength, and speed-agility. The severity of metabolic syndrome was determined using a MetS risk score derived from BMI z-score, HDL cholesterol, systolic blood pressure, triglycerides, and fasting glucose.

Based on the study, the researchers reported the following findings:

  • Lower limb muscular strength, assessed through the standing broad jump test, was significantly linked to reduced odds of metabolic syndrome.
  • A 1 standard deviation (24 cm) increase in jump distance was associated with a 53% lower risk (OR: 0.47).
  • Cardiorespiratory fitness and speed-agility did not show significant associations with metabolic syndrome or other cardiometabolic outcomes in this group.
  • Muscular strength demonstrated inverse relationships with BMI z-score, systolic blood pressure, and waist-to-height ratio.

These results emphasize the role of maintaining muscle integrity in supporting metabolic health during childhood and adolescence.

The authors noted that while the sample size was relatively small, the study maintained sufficient statistical power and followed strict ethical and methodological guidelines, including the STROBE recommendations. They acknowledged that the cross-sectional design limits causal interpretation, but the findings provide valuable insights into the linear relationship between physical fitness components and metabolic syndrome risk in children with obesity.

Importantly, this is the first study to explore these associations in Italian children and adolescents with obesity using a comprehensive battery of physical fitness tests. The findings emphasize the need to integrate muscle-strengthening activities into early-life physical activity programs to promote balanced growth, skeletal muscle health, and long-term prevention of metabolic diseases.

“Educating children about the importance of daily physical activity from a young age is crucial for fostering lifelong healthy habits,” the authors stated, adding that public health initiatives should prioritize strategies to enhance muscular strength among pediatric populations at risk.

The authors concluded, “By encouraging regular physical activity and incorporating targeted strength exercises, healthcare providers and caregivers can play a vital role in reducing metabolic risks and supporting overall health in children struggling with obesity.”

Reference:

Vandoni, M., Gatti, A., Carnevale Pellino, V. et al. Exploring the link between metabolic syndrome risk and physical fitness in children with obesity: a cross-sectional study. Eur J Pediatr 184, 497 (2025). https://doi.org/10.1007/s00431-025-06339-7

Powered by WPeMatico

Global rise in many Early-Onset GI cancers with colorectal cancer leading the trend, reveal two Dana-Farber reviews

Early-onset gastrointestinal (GI) cancers are rising at alarming rates worldwide and, in the U.S., are increasing faster than any other type of early-onset cancer, including breast cancer, according to two recent literature reviews from Dana-Farber Cancer Institute.

“Early-Onset Gastrointestinal Cancers: A Review,” published today in JAMA, provides a comprehensive analysis of the incidence, risk factors, and treatment approaches for early-onset GI cancers. Authors note the rising rate goes beyond colorectal cancer to include gastric, esophageal, and pancreatic cancers, among other less common GI malignancies. Early-onset GI cancer is typically defined as GI cancer diagnosed in adults younger than 50 years.

“Colorectal cancer is the most common early-onset GI cancer worldwide, accounting for more than half of the cases, but it is not the only GI cancer that is rising in younger adults. Unfortunately, pancreatic, gastric, and esophageal cancers are also increasing in young people,” said Dr. Kimmie Ng, senior author of the review and director of the Young-Onset Colorectal Cancer Center at Dana-Farber. “The rising incidence of early-onset GI cancers is alarming and underscores the need for enhanced prevention strategies and early detection methods.”

Of the GI cancers highlighted in the review, colorectal cancer is the only one currently with recommended screening guidelines for average-risk individuals in the U.S. Still, Dr. Ng says despite recommendations to begin colorectal cancer screening at age 45 for average-risk individuals, fewer than 1 in 5 (19.7%) U.S. adults aged 45 to 49 were screened in 2021, indicating a significant gap in early detection efforts.

“Screening adherence is absolutely critical,” says co-author Dr. Thejus Jayakrishnan, also of Dana-Farber. “We have strong evidence that colorectal cancer screening saves lives by reducing both the number of people who develop colorectal cancer and the number of people who die from it. Each missed screening is a lost opportunity to detect cancer early when it is more treatable, or to prevent cancer altogether by identifying and removing precancerous polyps.”

Steepest rise seen in youngest age groups: British Journal of Surgery review

The number of newly diagnosed cases of early-onset GI cancers rose by 14.8 percent between 2010 and 2019, noted a similar review published earlier this month in the British Journal of Surgery. The review notes the rise in early-onset cases disproportionately affects people who are Black, Hispanic, of Indigenous ancestry, and women.

Dr. Ng is senior author of that review. Dr. Sara Char, of Dana-Farber, and Catharine O’Connor, a medical student at Harvard Medical School, are co-first authors.

The count of early-onset GI cases is highest in the oldest group – people aged 40 to 49 – but the rise in rates is progressively steeper in younger groups. For example, people born in 1990 are twice as likely to develop colon cancer and four times as likely to develop rectal cancer compared to those born in 1950, according to the authors.

The authors also note that recent data from the Centers for Disease Control and Prevention (CDC) indicated a more than tripling of the incidence of colorectal cancer in people aged 15 to 19 and a near doubling in people aged 20-24.

Reviews offer comprehensive look at risk factors, treatment, and prognosis

Together, these two review papers observe several common risk factors associated with early-onset GI cancers. Modifiable lifestyle factors listed as significant contributors to the development of these cancers include obesity, poor diet, sedentary lifestyle, smoking, and alcohol consumption.

Nonmodifiable factors include family history and hereditary syndromes like Lynch syndrome. The JAMA review found 15% to 30% of these cancers have pathogenic germline variants, indicating a hereditary predisposition to developing cancer. Both reviews emphasize the importance of genetic testing for all patients with early onset GI cancers to assess familial risk of cancer and to guide treatment.

Treatment approaches for early-onset GI cancers are similar to those for later-onset cases, and may involve chemotherapy, surgery, and radiation, depending on the stage of the cancer. However, both papers found that patients with early-onset cancers often receive more aggressive treatment but may have similar or shorter survival rates compared to older patients.

The authors advocate for the establishment of specialized centers with multidisciplinary teams to support patients with early-onset GI cancers, addressing unique challenges such as fertility preservation, parenting, and psychosocial distress.

“Taken together, these two reviews are a call to action for further research on why rates of GI cancers are increasing in younger adults,” said Ng. “There is currently limited data available, especially in pancreatic, gastric, and esophageal cancers. This comprehensive look at what data exist can help raise education and awareness which is important because as a collective group, digestive system cancers account for a significant proportion of cancer-related deaths in younger adults in the U.S. and around the world.”

Reference:

Jayakrishnan T, Ng K. Early-Onset Gastrointestinal Cancers: A Review. JAMA. Published online July 17, 2025. doi:10.1001/jama.2025.10218

Powered by WPeMatico

Hospitalisation in COPD Patients Linked to Sharp Rise in Cardiovascular Events and Mortality: Study

UK: A recent study published in the International Journal of Chronic Obstructive Pulmonary Disease highlights a concerning link between hospitalisation in individuals with chronic obstructive pulmonary disease (COPD) and a significantly heightened risk of major adverse cardiovascular events (MACE) and mortality within the year following discharge.

Conducted by Anne E. Ioannides and her colleagues at the School of Public Health, Imperial College London, the prospective cohort study utilised electronic health records from across England between 2010 and 2019. Researchers analysed data from the Clinical Practice Research Datalink Aurum, which was linked with hospital and mortality records, to assess outcomes in COPD patients who experienced at least one hospitalisation compared to those who did not.

The study focused on two primary outcomes: non-fatal MACE—including acute coronary syndrome, arrhythmia, heart failure, or ischemic stroke—and cause-specific mortality over one year post-hospitalisation. Participants were stratified based on whether the hospitalisation was elective or emergency, and by the cause of admission (cardiovascular, respiratory, or other causes).

The following were the key findings of the study:

  • Cardiovascular risk significantly increased in COPD patients following hospitalisation.
  • Emergency hospitalisation was associated with an eight-fold higher risk of major cardiovascular events within one year (adjusted hazard ratio [aHR] 8.85).
  • Elective hospitalisations were linked to a seven-fold increase in cardiovascular event risk (aHR 7.04) compared to those who were not hospitalised.
  • All-cause mortality was notably higher after hospitalisation, especially for emergency admissions (aHR 2.49).
  • Elective cardiovascular hospitalisations did not show a significant rise in mortality risk.
  • The cause and type of hospitalisation influenced cause-specific mortality outcomes.
  • Respiratory-related hospitalisations were more likely to lead to respiratory-related deaths, highlighting a connection between the reason for admission and the eventual cause of death.

The researchers acknowledged several limitations, including potential misclassification of disease causes and lack of data on in-hospital treatments or medication use. Nonetheless, the study leveraged a robust dataset representative of the UK population and employed validated methodological approaches, including sensitivity analyses and propensity score adjustments.

From a clinical and public health standpoint, the study emphasizes the need for proactive cardiovascular screening and management in all COPD patients following hospitalisation, regardless of the reason for admission. Given that cardiovascular disease often remains underdiagnosed and undertreated in COPD patients, hospitalisation presents a key opportunity to initiate preventive strategies aimed at reducing MACE and mortality.

The study concludes that every hospital encounter for individuals with COPD should be viewed as a critical juncture to assess and manage cardiovascular risks. By doing so, healthcare systems may help mitigate the often-overlooked burden of cardiovascular complications and improve long-term outcomes in this high-risk population.

Reference:

Ioannides AE, Whittaker HR, Quint JK. Major Adverse Cardiovascular Events and Cause-Specific Mortality After Hospitalisation in COPD. Int J Chron Obstruct Pulmon Dis. 2025;20:2549-2560

https://doi.org/10.2147/COPD.S529171

Powered by WPeMatico

Cardiometabolic Diseases Significantly Accelerate Onset and Worsening of Neuropsychiatric Disorders: Study Finds

China: Individuals with cardiometabolic diseases (CMDs) such as type 2 diabetes, hypertension, ischemic heart disease, and stroke are at a significantly elevated risk of developing neurological and psychiatric disorders—and of progressing to more severe neuropsychiatric conditions and death—according to a large-scale longitudinal study published in Diabetes, Obesity and Metabolism.

The research, conducted by Jiang Li, MPH, from the Institute and Department of Endocrinology and Metabolism at Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, and colleagues, examined the long-term impact of CMDs on mental and neurological health. The team analyzed data from over 400,000 individuals enrolled in the UK Biobank, following them for a median period of 14.1 years.

The study focused on the progression from being neurologically and psychiatrically healthy to developing a first neuropsychiatric disorder (FNPD), progressing to neuropsychiatric multimorbidity (NPM)—defined as the coexistence of at least two conditions such as dementia, Parkinson’s disease, depression, anxiety, or sleep disorders—and finally to death.

The key findings of the study were as follows:

  • There was a strong association between cardiometabolic diseases (CMDs) and all stages of neuropsychiatric disorder progression.
  • Each additional CMD increased the risk of developing a first neuropsychiatric disorder by 28%.
  • The presence of more CMDs raised the likelihood of progressing from a single neuropsychiatric condition to neuropsychiatric multimorbidity by 7%.
  • The risk of death from any stage of neuropsychiatric disorder progression increased by up to 38% with each added CMD.

When researchers broke down the transitions by specific neuropsychiatric conditions, they observed that the relationship between CMDs and neuropsychiatric outcomes varied depending on the type and combination of CMDs present. This highlights the complexity and interplay between physical and mental health conditions.

“Cardiometabolic diseases appear to play a key role at nearly every stage of neuropsychiatric deterioration,” the authors noted. “Their impact is not limited to the initial onset of disorders but extends to the worsening of neuropsychiatric burden and increased mortality.”

The study’s results were further supported by analyses from a separate Chinese population cohort in the China Health and Retirement Longitudinal Study (CHARLS), reinforcing the generalizability of these findings across populations.

These insights have significant implications for public health and clinical care. The researchers emphasized the urgent need for integrated approaches to managing CMDs, not only to reduce cardiovascular risk but also to prevent the onset and worsening of neuropsychiatric illnesses.

The study highlights the importance of early detection and comprehensive management of cardiometabolic health as a potential strategy to curb the rising burden of mental and neurological disorders, particularly in aging populations.

Reference:

Li J, Xu X, Sun Y, Yu Y, Fu Y, Tan X, He L, Wang N, Lu Y, Wang B. Cardiometabolic diseases and dynamic transitions of neuropsychiatric disorders: A longitudinal trajectory analysis. Diabetes Obes Metab. 2025 Jul 16. doi: 10.1111/dom.16614. Epub ahead of print. PMID: 40667714.

Powered by WPeMatico

Regular opioid use may increase dementia risk, reveals research

In a study published in Alzheimer’s & Dementia, a team led by Dr. SHA Feng from the Shenzhen Institute of Advanced Technology of the Chinese Academy of Sciences, collaborating with Dr. Jed A. Barash from the Massachusetts Veterans Home at Chelsea and Prof. W. Andrew Kofke from the University of Pennsylvania, found that regular opioid use is associated with an increased risk of dementia, particularly vascular dementia.

Chronic non-cancer pain (CNCP) is defined as any painful condition that persists for more than three months and is unrelated to malignancy. Opioid use for CNCP became widespread in the mid-1990s. Inappropriate prescribing, dependence, and misuse of high-potency opioids have raised public health concerns.

Previous studies have suggested that opioid use may affect the endogenous opioid system and potentially impair the hippocampus and other central nervous system regions, increasing the risk of cognitive decline and dementia.

In this study, the researchers conducted a prospective cohort study involving 197,673 individuals with CNCP aged 37 to 73 from the UK Biobank, with a mean follow-up of 13.8 years. They applied multiple Cox, linear, and logistic regression models, which control for potential confounding factors, to explore the associations between regular opioid use and incident dementia, neuroimaging outcomes, and cognitive measures.

The researchers found that regular opioid use was associated with a 20% higher risk of all-cause dementia compared with taking analgesics. Participants who regularly used strong opioids had a over 70% increased risk of dementia, and those taking non-opioid analgesics showed a risk level similar to the non-users. Besides, a significant association between opioid use and vascular dementia (VD) was observed.

Through neuroimaging analyses, the researchers found that regular use of strong opioids was linked to reduced total brain volume (TBV), white matter volume (WMV), and hippocampal volume (HV). They also found that opioid use was associated with lower fluid intelligence, but not significantly associated with prospective memory decline.

This study underscores the importance of considering both opioid potency and cumulative exposure when evaluating the associations between opioid use and the risk of dementia or other adverse outcomes. This study provides valuable insights into the strategies for addressing the complex interplay between chronic pain, analgesic use, and cognitive impairment.

Reference:

Tengfei Lin, Jed A. Barash, Shiyu Wang, Fuxiao Li, Zhirong Yang, W. Andrew Kofke, Feng Sha, Jinling Tang, Regular use of opioids and dementia, cognitive measures, and neuroimaging outcomes among UK Biobank participants with chronic non-cancer pain, Alzheimer’s & Dementia, https://doi.org/10.1002/alz.70177.

Powered by WPeMatico

Ketamine use in chronic pain unsupported by evidence, review finds

The off-label use of ketamine to treat chronic pain is not supported by scientific evidence, a new Cochrane review has found.

Powered by WPeMatico

COVID infection ages blood vessels, especially in women, research reveals

A COVID infection, particularly in women, may lead to blood vessels aging around five years, according to research published in the European Heart Journal.

Powered by WPeMatico

A stroke stole her ability to speak—18 years later, scientists used AI to bring it back

Ann Johnson became paralyzed after a brainstem stroke at age 30. As a participant in a clinical trial led by researchers at UC Berkeley and UC San Francisco, she finally heard her voice again.

Powered by WPeMatico

Why is research into women’s mental health decades behind?

A global mental health crisis is evolving. And at the forefront of the surging rates of mental health disorders globally are women, who are disproportionately affected when compared to men.

Powered by WPeMatico

A rare ‘brain-eating amoeba’ has been detected in Queensland water. Is tap water safe?

One of the world’s most dangerous water-borne microorganisms, commonly called a “brain-eating amoeba,” has recently been detected in two drinking water supplies in southwest Queensland.

Powered by WPeMatico